Objective: Evaluating the diagnostic performance of SVM to classify benign and malignant by performing a meta-analysis.
Methods: The data used for this study were secondary data. It consisted of 221 mammogram images (mean age 57.5 years) with 164 malignant and 57 benign, taken from a radiological database that has been examined by a radiologist with more than 20 years of experience. Also, histopathological record data that had been examined by an oncologist with more than 20 years of experience. Mammograms were taken from January 2022 to June 2022. In all, 221 mammograms consisting of 164 malignant and 57 benign were used as SVM method training, and 20 mammograms consisting of 10 malignant and 10 benign were used to test the performance of the SVM method. It was then evaluated using pathology results as the gold standard.
Results: Benign had a significantly lower deviation (an average of 29.2661230 ± 10.14916673) than malignant (an average of 33.1841234 ± 11.70238757). The SVM method performance value obtained the values of TP, FP, TN, FN, accuracy, sensitivity, Specificity, and Precision, respectively 7,7, 3, 3, 50%, 70%, 30%, and 50%.
Conclusion: A proper performance to distinguish benign and malignant can be obtained using the physical deviation parameters with the SVM classification approach. However, these findings should be proven in larger datasets with different mammographic scanners. Our meta-analysis shows that the physical parameters and SVM have high sensitivity but low specificity. Of the nine physical parameters in the mammogram, only the parameter deviation was significant to distinguish between benign and malignant. The SVM method proved to be able to differentiate between benign and malignant.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.